170 related articles for article (PubMed ID: 27771291)
1. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.
Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
Rosenberg AS; Klein AK; Ruthazer R; Evens AM
Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
[TBL] [Abstract][Full Text] [Related]
3. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients.
Karuturi M; Shah N; Frank D; Fasan O; Reshef R; Ahya VN; Bromberg M; Faust T; Goral S; Schuster SJ; Stadtmauer EA; Tsai DE
Transpl Int; 2013 Jun; 26(6):616-22. PubMed ID: 23551167
[TBL] [Abstract][Full Text] [Related]
6. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report.
Thibaud V; Rivalan J; Llamas F; Cherel M; Decaux O; Vigneau C
Nephrol Ther; 2018 Dec; 14(7):544-547. PubMed ID: 30301610
[TBL] [Abstract][Full Text] [Related]
8. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
Milano AF
J Insur Med; 2018; 47(4):203-211. PubMed ID: 30668210
[TBL] [Abstract][Full Text] [Related]
10. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant lymphoproliferative disease and survival in adult heart transplant recipients.
Hayes D; Tumin D; Foraker RE; Tobias JD
J Cardiol; 2017 Jan; 69(1):144-148. PubMed ID: 26972343
[TBL] [Abstract][Full Text] [Related]
12. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C;
Eur J Haematol; 2019 Jun; 102(6):465-471. PubMed ID: 30828868
[TBL] [Abstract][Full Text] [Related]
13. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.
Luskin MR; Heil DS; Tan KS; Choi S; Stadtmauer EA; Schuster SJ; Porter DL; Vonderheide RH; Bagg A; Heitjan DF; Tsai DE; Reshef R
Am J Transplant; 2015 Oct; 15(10):2665-73. PubMed ID: 25988622
[TBL] [Abstract][Full Text] [Related]
14. Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):235-42. PubMed ID: 23538344
[TBL] [Abstract][Full Text] [Related]
15. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
17. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
19. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression.
Caillard S; Dharnidharka V; Agodoa L; Bohen E; Abbott K
Transplantation; 2005 Nov; 80(9):1233-43. PubMed ID: 16314791
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Yeung S; Stephens D; Punnett AS; Barton M; Allen UD
Transplantation; 2019 Nov; 103(11):e369-e374. PubMed ID: 31385930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
